Panelists discussed asking commercial laboratories to build reflex quantitative HBsAg testing after a positive surface antigen result, although one participant noted this can be difficult to set up. Without it, patients managed in primary care may never learn whether they are candidates for the functional cure.
How Specialists Are Using Quantitative HBsAg Testing
Participants
- Tatyana Kushner, MD, MSCE, Weill Cornell Medicine (moderator)
- Kristina Chacko, MD, FAASLD, Montefiore-Einstein Center for Transplantation
- Ype P. de Jong, MD, PhD, Weill Cornell Medicine
- Saikiran M. Kilaru, MD, NYU Langone Health
- Tibor Krisko, MD, Weill Cornell Medicine
- Mark Makhinson, PharmD, Mount Sinai Health System
- Rebecca Roediger, MD, Weill Cornell Medicine
- Mark S. Sulkowski, MD, Johns Hopkins University School of Medicine
- Su Wang, MD, MPH, FACP, RWJBarnabas Health
Few patients arrive at specialty clinics with a quantitative HBsAg result, the specialists said. Mark S. Sulkowski, MD, of Johns Hopkins University School of Medicine, has tested patients at initial evaluation and annually for 4 years and said the result shows how close treated patients may be to functional cure. Ype P. de Jong, MD, PhD, of Weill Cornell Medicine, now orders it at return visits for all patients with CHB.
One panelist said that once the test is available in the EHR, ordering is simple, but it did take his health system nearly 2 years to get it added. Another said that having to order through commercial laboratories had limited how often he tested.
Because participants in the phase 3 trial for bepirovirsen had to be on nucleos(t)ide analogue (NA) therapy, faculty said they are starting NAs in gray-zone patients with low HBsAg who previously declined treatment. Several also treat beyond guideline thresholds, calling alanine aminotransferase (ALT) cutoffs outdated and weighing fibrosis, age, viral load, and family history of liver cancer instead.
What Weekly Bepirovirsen Monitoring Demands From Health Systems
Patients used to a daily pill and twice yearly visits will face about 6 months of weekly injections and labs to monitor ALT flares and low platelet counts once on bepirovirsen. Mark Makhinson, PharmD, of Mount Sinai Health System, noted that most of the large health systems at the roundtable, in the New York–New Jersey area, have robust specialty pharmacy programs that handle prior authorization, financial assistance, and monthly adherence checks through in-house specialty pharmacies.
"I think it's really positive, but...that is likely not the norm everywhere," Makhinson said.
Sulkowski said the group is working to rebuild the hepatitis C–era pharmacy partnerships that have largely been dismantled and to concentrate prescribing among a few bepirovirsen champions rather than all 15 clinicians who treat hepatitis B. Advanced practice providers would handle follow-up, with 340B Drug Pricing Program revenue justifying the hires. Wang suggested standing weekly lab orders, telehealth support, and ECHO-style learning networks to extend capacity beyond specialists.
A roughly 1-in-5 chance of functional cure is progress, the participants said, but it calls for candid conversations with patients about the odds. One panelist wants real-world data in their own patient population before committing patients to roughly 20% odds of cure. Wang said one benefit goes unmeasured in trials: relief from the stigma of living with hepatitis B.
"Patients, they feel infectious; [then] they worry about giving it to their family members, and there's a shame about that," Wang said. "Being able to say, 'I lost my surface antigen' is very liberating for them."
References
- McCormick B. Bepirovirsen approval offers new option for chronic HBV treatment. AJMC®. October 21, 2026. Accessed November 17, 2026. https://www.ajmc.com/view/bepirovirsen-approval-offers-new-option-for-chronic-hbv-treatment
- Hou J, Lim SG, Buti M, et al. Phase 3 results of bepirovirsen treatment for chronic hepatitis B virus infection. N Engl J Med. 2026;394(24):2395-2406. doi:10.1056/NEJMoa2515131
- Hepatitis B Foundation. U.S. screening recommendations. Accessed November 17, 2026. https://www.hepb.org/prevention-and-diagnosis/u-s-screening-recommendations/